Kornimate/medical-research-clean huggingface dataset:
study of zg005 in combination with etoposide and cisplatin in participants with advanced neuroendocrine carcinoma.

Conditions: Neuroendocrine Carcinoma

Summary: the trial is divided into two parts. part 1 is a dose escalation study of the zg005 combined with etoposide and cisplatin, primarily assessing the tolerability and safety of this combined treatment. part 2 is a dose expansion study, further evaluating the preliminary efficacy and safety of this combined treatment.


Eligibility criteria:
inclusion criteria: * fully understand the study and voluntarily sign the informed consent form. * male or female 18-70 years of age. * eastern cooperative oncology group (ecog) performance status of 0-1. * histologically confirmed recurrent or metastatic neuroendocrine carcinoma * life expectancy ≥ 3 months. exclusion criteria: * medical history, computed tomography or magnetic resonance imaging results indicate that existence of the central nervous system metastases; * any other malignancy within 5 years. * participants were deemed unsuitable for participating in the study by the investigator for any reasons.
leveraging wechat social-media and messaging platform to increase physical activity in chinese glaucoma patients

Conditions: Glaucoma

Summary: the positive effects of exercise on ocular health are known, but modern lifestyles have made it difficult to incorporate physical activity into the daily lives of the chinese population. recent studies suggest that exercise plays an important role in lowering intraocular pressure (iop) by protecting retinal ganglion cells (rgcs) in glaucoma patients as well as other potential neuroprotective benefits. increasing the amount of physical activity within the chinese glaucoma population may have marked effects on health outcomes and coincides with the chinese government's efforts to make exercise an urgent public health priority. there is a need for innovative, cost-effective, and proven interventions to promote exercise behavior change and social media platforms may be able to fill this niche. wechat is china's largest and most frequently used social media and messaging application with an estimated 570 million users. the platform has been found to be a useful tool in healthcare settings to promote weight-loss, health literacy, and patient adherence in chinese populations. this study is a 5-weeks randomized control trial with three total study visits. 80 patients from an academic glaucoma clinic in wenzhou medical college will be randomized into two groups. the intervention group will be enrolled into an official wechat group and receive periodic reminders to exercise, health education materials, and motivational incentives. the control group will receive weekly reminders and leaflets at the first clinic visit. patients' daily step data will be monitored using an accelerometer wgt3x-bt. the intervention duration will include an initial clinic visit, a one-week follow-up after wearing the accelerometer, and then a subsequent one-month follow-up visit after wearing the accelerometer. at the one-week visit the patient will be randomized and at the subsequent one-month visit there will be a close-out discussion about the study. in addition to collecting step data at clinic visits, investigators will also measure patients' visual field tests, optical coherence tomography angiography (angio-oct), and intraocular pressure (iop) using goldmann tonometry. the investigators' hypothesis is that using an official wechat patient group will be a robust and effective stimulus to increase physical exercise.


Eligibility criteria:
inclusion criteria: * glaucoma diagnosis * age 40 years and above * ability to sign informed consent * ability to use wechat exclusion criteria: * patients with severe heart, lung, or kidney disease which may prevent them from exercising * patients who self-report walking 12,000 steps or more per day
wound vitality markers in forensic pathology

Conditions: Wound

Summary: the purpose is to determine intrinsic properties of various immunohistochemical markers (fviiira, cd15, cd30, tryptase, tnfα, il-1β, tgfα et tgfβ1) for diagnosis of vital wound, alone and in association (evaluation of sensibility with surgery wounds and evaluation of specificity with post-mortem wounds). secondary purposes are to measure the minimum time to obtain a positive labeling in vital wounds, and to evaluate inter-observer reproducibility of vitality diagnosis with different markers. expression of microrna mir 9, mir 21 et mir 198 will be also studied.


Eligibility criteria:
inclusion criteria: alive persons: - abdominoplasty deceased persons: - medico-scientific autopsy for diagnosis exclusion criteria: alive persons: * fragmented sample with non-visible banks * cutaneous pathology deceased persons: * persons under protection * medico-legal obstacle * cutaneous pathology
tetralogy of fallot seed grant

Conditions: Pulmonary Regurgitation After Repair of Tetralogy of Fallot

Summary: patients with pulmonary regurgitation after surgical correction of tof over 13 years old will be recruited from the ucsf adult congenital heart disease clinic. since there is no data in the literature describing the prevalence of abnormal mri volumetric and functional parameters in asymptomatic patients with pr after tof repair, a pilot study with 30 patients will be conducted. increase in sample size may be necessary in the future to accurately interpret the data. after informed consent is obtained, clinical history and physical examination as well as review of old charts will be performed to characterize these patient's clinical status. all patients will undertake a graduated supine bicycle exercise test with mvo2 measurement to assess exercise capacity. mri studies will be performed in a 1.5 tesla unit. ssfp cine images will be obtained in the short-axis plane encompassing the entire heart. velocity-encoded cine mr images will be obtained perpendicular to the direction of blood flow in the main pulmonary artery. volumetric and flow analysis will be performed in a separate dedicated workstation by a radiologist. end-diastolic volume, end-systolic volume, ejection fraction, total ejection fraction and pulmonary regurgitant fraction will be calculated.


Eligibility criteria:
inclusion criteria: patients over 13 years of age with pulmonary regurgitation after surgical correction of tetralogy of fallot. 1. adult patients with pulmonary regurgitation after surgical repair of tetralogy of fallot who are under follow-up at the adult congenital heart disease clinic at ucsf or 2. pediatric patients with pulmonary regurgitation after surgical repair of tetralogy of fallot who are under follow-up at the pediatric congenital heart disease clinic at ucsf and are referred for a clinically indicated cardiac mri studies or 3. adult and pediatric patients with pulmonary regurgitation after surgical repair of tetralogy of fallot who are referred for clinically indicated mri studies at ucsf. exclusion criteria: contraindication for mri study. claustrophobia.

Keywords: pulmonary regurgitation tetralogy of fallot
continued safety and immunogenicity study of a live francisella tularensis vaccine

Conditions: Tularemia

Summary: this study is designed to determine the safety and immunogenicity of a live francisella tularensis vaccine

study objectives: 1. to assess the safety of live f. tularensis vaccine ndbr 101. 2. to assess the immunogenicity of live f. tularensis vaccine ndbr 101.

Eligibility criteria:
inclusion criteria: 1. at least 18 years old. 2. females of childbearing potential must agree to have a urine or serum pregnancy test on vaccination day, immediately before vaccination (exception: documented hysterectomy or \> 3 years of menopause). the results must be negative. subjects must agree not to become pregnant for 3 months after receipt of the vaccine. 3. subjects must be at risk for exposure to f. tularensis. 4. subjects must have an up-to-date (within 1 year) medical history including concomitant medications, physical examination, and laboratory tests on their charts and be medically cleared for participation by an investigator. 5. subject must be willing to return for all follow-up visits on days 1 and 2, between days 5-9, 12-16, 28-35, and 56-84 (if needed), all visits for serology, and the closeout interview 6 months (±14 days) after vaccination or revaccination. 6. subject must agree to report any adverse event which may or may not be associated with administration of the test article for at least 28 days after vaccination. exclusion criteria: 1. over the age of 65 years. 2. vaccinated against tularemia within the last 10 years or had a documented, confirmed tularemia infection. 3. clinically significant abnormal lab results including evidence of hepatitis c, hepatitis b carrier state, or elevated liver function tests (two times the normal range or at the discretion of the pi). 4. personal history of an immunodeficiency or current treatment with an oral or intravenous immunosuppressive medication. 5. confirmed hiv\* infection. 6. a medical condition that, in the judgment of the principal investigator (pi), would impact subject safety. 7. antibiotic therapy within 7 days before vaccination. 8. pregnancy or lactation. subjects must agree not to become pregnant for 3 months after receipt of the vaccine. 9. any known allergies to any component of the vaccine: modified casein partial hydrolysate medium glucose cysteine hemin agar sucrose gelatin agar stabilizer 10. administration of another vaccine within 4 weeks of tularemia vaccination. 11. any unresolved ae resulting from a previous immunization.

Keywords: live vaccine strain (lvs)
the effect of compression time for secure stapling with a linear stapler in laparoscopic gastric bypass surgery

Conditions: Bleeding of the Staple Line

Summary: bleeding from the staple line is a complication of linear stapling. after clamping, a short period after firing of the laparoscopic linear stapler is recommended. that is, the clinician should continue to press the tissue between the prongs of the device to achieve adequate hemostasis at the staple line. the significance of the waiting period for hemostasis at the staple line has not been empirically clarified in humans. in this study, the investigators compared the number of bleeding points use of the laparoscopic linear stapler. consequently, the investigators assessed the effects of time after the firing of linear stapling in patients who underwent laparoscopic gastric bypass.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of morbid obesity * must be laparoscopic surgery exclusion criteria: * usage of anti-coagulant * presence of impaired blood clotting
connected rehabilitation: an alternative to conventional cardiovascular rehabilitation?

Conditions: Coronary Artery Disease

Summary: cardiovascular rehabilitation (cvr) has major beneficial effects by improving physical capacity, accelerating return to activities and reinsertion and reducing mortality. it associates reconditioning to effort and therapeutic education for the optimal control of " risk factors ". it corresponds to a global approach to patients, thus counterbalancing the tendency to hyperspecialise in medicine. however, because of the lack of specialised centres, only a small proportion of patients (≈30%) are able to benefit. numerical tools used in e-health, the deployment of the internet and certain " connected " devices may provide alternatives outside hospital, by enabling the follow-up of patients and their physiological parameters (heart rate, blood pressure, weigh, physical activity...), and the adaptation - using an interactive web platform - of the physical activity programme, nutrition, compliance with medication and weaning from smoking. this project proposes to evaluate the effects of a so-called " connected " cvr programme, and to show its non-inferiority compared with a conventional cvr.


Eligibility criteria:
inclusion criteria: * men or women, * aged between 30 and 75 years, * presenting coronary artery disease without heart failure (left ventricular ejection fraction on echocardiography (simpson method) \> 45 %). * patients who have provided written consent. exclusion criteria: * adults under guardianship * patients without national health insurance cover * pregnant or breastfeeding women * inability to use connected numeric devices even simple operations (tablette, cardiofrequency meter, bp monitor...) * heart failure, with a low or preserved left ventricular ejection fraction * contra-indication for cardiovascular rehabilitation : * severe obstructive heart disease (severe and asymptomatic obstacle to left ventricular ejection) * acute unstable coronary syndrome * tight aortic valve stenosis * severe progressive cardiac rhythm or conduction disorders without pacing and discovered during the initial stress test * intracavitary thrombus * presence of moderate to severe pericardial effusion * severe pulmonary artery hypertension (systolic pap \>70mmhg) * recent history of venous thromboembolism (previous 3 months) * progressive inflammatory or infectious disease * inability to engage in physical exercise * impaired executive functions making it impossible to understand and comply with the cvr programme (mini mental test \< 24) * heart transplant * associated medical condition likely to impair functional capacities (examples: non-stabilised metabolic disorders such as progressive kidney failure, severe asthenia related to a severe non-stabilised disorder such as neoplasm, systemic diseases...) * physical disability in the lower limbs that could hamper reconditioning, whether neurological (central or peripheral), arterial (in particular, peripheral artery disease with a systolic index \< 0.6) or orthopaedic (degenerative or inflammatory rheumatism)
a pilot study on neuroimaging in scd: part of the boston consortium to cure sickle cell disease

Conditions: Sickle Cell Disease

Summary: sickle cell disease (scd) impairs oxygen transport to tissue and causes endothelial injury. thus, therapeutic interventions aim to improve both, but there is an unmet need for biomarkers to determine when intervention is necessary and evaluate the effectiveness of the chosen intervention in individual patients. this study proposes to monitor scd and its treatment through their impact on cerebral hemodynamics, as the brain is one of the most vulnerable and consequential targets of the disease. specifically, this study will optimize quantitative magnetic resonance imaging (mri) and advanced optical spectroscopy techniques such as frequency-domain near-infrared and diffuse correlation spectroscopies (fdnirs-dcs) to monitor 1) cerebral oxygen transport with measures of cerebral blood flow (cbf), cerebral oxygen extraction fraction (oef) and cerebral metabolic rate of oxygen consumption (cmro2) and 2) endothelial function with cerebrovascular reactivity (cvr). additionally, this study aims to monitor baseline cerebral oxygen transport and cvr, as well as changes that occur with treatment (transfusion or genetic therapy to induce fetal hemoglobin) and assess hemoglobinopathy patients with known genotypes and phenotypes. the ultimate goal is to demonstrate the potential of this monitoring approach to select individual scd subjects for interventions and evaluate individual responses to treatment. success will help justify inclusion of these modalities in ongoing and future clinical trials of novel scd therapies.


Eligibility criteria:
inclusion criteria: group 1 (healthy controls): * children ages 8-18 without scd group 2 (scd patients without treatment): * scd patients ages 8-18 who: * have not undergone gene therapy or a bone marrow transplant * are not receiving chronic transfusions * have not received a blood transfusion in the past 3 months group 3 (scd patients who have undergone gene therapy): * scd patients ages 8-18 who have had gene therapy at least one month prior to enrollment group 4 (scd patients who have chronic transfusions): * scd patients ages 8-18 who receive chronic transfusions exclusion criteria: * electrical implants such as cardiac pacemakers or perfusion pumps; * ferromagnetic implants such as aneurysm clips, surgical clips, prosthesis, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants; * ferromagnetic objects such as jewelry or metal clips; * women of childbearing age who are seeking to become pregnant, who are breastfeeding, or who suspect they may be pregnant; * pre-existing medical conditions including a likelihood of developing seizures or claustrophobic reactions; * any greater than normal potential for cardiac arrest; * subjects requiring sedation for mri

Keywords: sickle cell mri near infrared spectroscopy (nirs)
magnesium treatment in hypoparathyroidism

Conditions: Hypoparathyroidism

Summary: study hypothesis: supplementary magnesium may influence the blood calcium level in treated hypoparathyroid patients. patients will be treated with supplementary magnesium (350 mg/day) for 3 weeks. calcium and other relevant blood parameters will be measured before the treatment, at the end of treatment and 2 weeks after stopping treatment.


Eligibility criteria:
inclusion criteria: * primary or secondary hypoparathyroidism * treatment with calcium plus vitamin d analogue * ionized calcium 1,0-1,29 mmol/l * magnesium level 0,7-1,05 mmol/l * tsh 0.1- 10 imu/l exclusion criteria: * any other disease known to influence plasma ca level * pregnancy * creatinine \> 150 microm/l * patient has used supplementary magnesium within 2 previous months

Keywords: primary hypoparathyroidism secondary hypoparathyroidism magnesium
fuzheng huayu tablets against posthepatitic cirrhosis

Conditions: Posthepatitic Cirrhosis

Summary: the primary purpose of the trial is adopted fuzheng huayu tablets against posthepatitic cirrhosis, and to build a standard evaluation system for efficacy of traditional chinese medicine (tcm). the second purpose is according to the international clinical guideline and the specialty of tcm to build a standard clinical trial regulation for traditional chinese medicine.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of b post hepatitic cirrhosis. * male or female patients between 18\~65 years old. * written informed consent. exclusion criteria: * child-pugh c above 12, or alt \> 2×uln, tbil \> 2×uln, or combined with hepatic encephacopathy, obstinate ascites, bleeding tendency, hepato-renal syndrome, or primary liver cancer. * combined with severe heart, gallbladder, kidney, endocrine system, hemopoietic system or nervous system disease. * deformed man by the law. * pregnancy or breast feeding women, or unwilling to have contraception. * irritability body constitution, or irritability of the fuzheng huayu capsules. * enter other trials lately one month. * other cause of cirrhosis.

Keywords: fuzheng huayu tablets multicenter clinical study
characteristics of patients with covid-19 in meta state, colombia

Conditions: COVID; SARS-CoV 2; SARS Pneumonia; SARS (Disease); SARS (Severe Acute Respiratory Syndrome)

Summary: this observational study aims to collect detailed clinical information on confirmed or suspected patients of covid-19 treated in hospitals from meta state, colombia. the objectives are: 1. to establish the characteristics of patients and healthcare workers treated with covid-19. 2. to assess previous predisposing morbidity. 3. to detail clinical factors associated with complications. 4. to profile clinical indicators for severity and outcomes.

hospital database and clinical charts in an electronic format of patients with suspected or confirmed covid-19 will be reviewed to include in the study. multiple centers from the eastern colombian prairies caring for this population will participate to provide an understanding of the behavior of the epidemic and accurate clinical comprehension of the disease. healthcare centers involved in providing an evaluation of patients infected with sars-cov-2 will be invited to participate. the study will focus on the routine or new treatment strategies provided and a large population of patients analyzed would be desirable. it will allow identifying the most relevant factors associated with clinical outcomes, complications, and prognosis, with an appropriate statistical methodology for the analysis of observational nature. variables of individuals assisted will be recorded as well as the end results, such as baseline characteristics of individuals and disease, and main outcomes such as mortality, need for icu attention, mechanical ventilation, and length of stay. these results will be used to promote an improvement in the quality of care and individual and cluster decisions in the region.

Eligibility criteria:
inclusion criteria: * patients admitted to participant institutions with respiratory symptoms or diagnosed as compatible with covid-19. exclusion criteria: * none.

Keywords: covid sars viral pneumonia sars-cov 2 coronavirus
the effect of growth hormone in very young girls with turner syndrome

Conditions: Turner Syndrome

Summary: this study investigated the effect of growth hormone on the growth of infants and toddlers with turner syndrome during 2 years of treatment with growth hormone. this was compared with the growth of infants and toddlers with turner syndrome who did not receive any growth hormone treatment. the overall aim was to prevent the growth failure usually seen during this period. the study also looked at middle ear disease, hearing problems, and cognitive and behavioral development.


Eligibility criteria:
inclusion criteria: * karyotype-proven turner syndrome that included a documented abnormality of the short arm of an x chromosome. * at least 9 months of age and not greater than 4 years of age. * normal values for age for hemoglobin, thyroid stimulating hormone (tsh) and urinalysis (office dipstick is adequate), performed prior to study entry. * if there was a known history of hypothyroidism, then adequate thyroid hormone replacement must have been taken for at least 6 months prior to study entry. exclusion criteria: * current or previous treatment with any therapy that may have directly influenced growth, including growth hormone, growth hormone-releasing hormone, estrogens and anabolic steroids such as oxandrolone. this included previous completion of, or withdrawal from, this study or any other study investigating therapeutic uses of growth hormone or growth hormone-releasing hormone. * chronic treatment with systemic glucocorticoids in supra-physiological doses. * treatment with potential growth-influencing medications such as methylphenidate (ritalin), pemoline (cylert), and amphetamines, at, or within 3 months prior to, study entry. * presence of any y chromosome component in the karyotype if gonads were in situ. subjects whose karyotype contained y chromatin, but who had undergone gonadectomy, were eligible to enter the study. * presence of any additional known autosomal abnormality.